These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 11595724)
1. Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice. Ng SS; Tsao MS; Nicklee T; Hedley DW Clin Cancer Res; 2001 Oct; 7(10):3269-75. PubMed ID: 11595724 [TBL] [Abstract][Full Text] [Related]
2. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Ng SS; Tsao MS; Nicklee T; Hedley DW Mol Cancer Ther; 2002 Aug; 1(10):777-83. PubMed ID: 12492110 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Ng SSW ; Tsao MS; Chow S; Hedley DW Cancer Res; 2000 Oct; 60(19):5451-5. PubMed ID: 11034087 [TBL] [Abstract][Full Text] [Related]
4. Dissociation of gemcitabine sensitivity and protein kinase B signaling in pancreatic ductal adenocarcinoma models. Pham NA; Tsao MS; Cao P; Hedley DW Pancreas; 2007 Oct; 35(3):e16-26. PubMed ID: 17895832 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Yau CY; Wheeler JJ; Sutton KL; Hedley DW Cancer Res; 2005 Feb; 65(4):1497-504. PubMed ID: 15735038 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Bondar VM; Sweeney-Gotsch B; Andreeff M; Mills GB; McConkey DJ Mol Cancer Ther; 2002 Oct; 1(12):989-97. PubMed ID: 12481421 [TBL] [Abstract][Full Text] [Related]
7. Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma. Simon PO; McDunn JE; Kashiwagi H; Chang K; Goedegebuure PS; Hotchkiss RS; Hawkins WG Int J Cancer; 2009 Aug; 125(4):942-51. PubMed ID: 19405118 [TBL] [Abstract][Full Text] [Related]
8. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Arlt A; Gehrz A; Müerköster S; Vorndamm J; Kruse ML; Fölsch UR; Schäfer H Oncogene; 2003 May; 22(21):3243-51. PubMed ID: 12761494 [TBL] [Abstract][Full Text] [Related]
9. Induction of apoptosis in tumor-associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice. Yokoi K; Kim SJ; Thaker P; Yazici S; Nam DH; He J; Sasaki T; Chiao PJ; Sclabas GM; Abbruzzese JL; Hamilton SR; Fidler IJ Neoplasia; 2005 Jul; 7(7):696-704. PubMed ID: 16026649 [TBL] [Abstract][Full Text] [Related]
10. PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells. Wang Y; Kuramitsu Y; Baron B; Kitagawa T; Tokuda K; Akada J; Maehara SI; Maehara Y; Nakamura K Int J Oncol; 2017 Feb; 50(2):606-612. PubMed ID: 28000865 [TBL] [Abstract][Full Text] [Related]
11. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma. Chen D; Niu M; Jiao X; Zhang K; Liang J; Zhang D Int J Mol Sci; 2012; 13(1):1186-1208. PubMed ID: 22312312 [TBL] [Abstract][Full Text] [Related]
13. Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Yokoi K; Sasaki T; Bucana CD; Fan D; Baker CH; Kitadai Y; Kuwai T; Abbruzzese JL; Fidler IJ Cancer Res; 2005 Nov; 65(22):10371-80. PubMed ID: 16288027 [TBL] [Abstract][Full Text] [Related]
14. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Yokoi K; Fidler IJ Clin Cancer Res; 2004 Apr; 10(7):2299-306. PubMed ID: 15073105 [TBL] [Abstract][Full Text] [Related]
15. Andrographolide causes apoptosis via inactivation of STAT3 and Akt and potentiates antitumor activity of gemcitabine in pancreatic cancer. Bao GQ; Shen BY; Pan CP; Zhang YJ; Shi MM; Peng CH Toxicol Lett; 2013 Sep; 222(1):23-35. PubMed ID: 23845849 [TBL] [Abstract][Full Text] [Related]
16. Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro. Kawasaki D; Emori Y; Eta R; Iino Y; Hamano H; Yoshinaga K; Tanaka T; Takei M; Watson SA Cancer Chemother Pharmacol; 2008 Apr; 61(5):883-92. PubMed ID: 17901954 [TBL] [Abstract][Full Text] [Related]
17. Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Schniewind B; Christgen M; Kurdow R; Haye S; Kremer B; Kalthoff H; Ungefroren H Int J Cancer; 2004 Mar; 109(2):182-8. PubMed ID: 14750167 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of PDGFR phosphorylation and Src and Akt activity by GN963 leads to therapy of human pancreatic cancer growing orthotopically in nude mice. Baker CH; Trevino JG; Summy JM; Zhang F; Caron A; Nesbit M; Gallick GE; Fidler IJ Int J Oncol; 2006 Jul; 29(1):125-38. PubMed ID: 16773192 [TBL] [Abstract][Full Text] [Related]
19. Mechanical stretch stimulates protein kinase B/Akt phosphorylation in epidermal cells via angiotensin II type 1 receptor and epidermal growth factor receptor. Kippenberger S; Loitsch S; Guschel M; Müller J; Knies Y; Kaufmann R; Bernd A J Biol Chem; 2005 Jan; 280(4):3060-7. PubMed ID: 15545271 [TBL] [Abstract][Full Text] [Related]
20. Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma. Al-Ejeh F; Pajic M; Shi W; Kalimutho M; Miranda M; Nagrial AM; Chou A; Biankin AV; Grimmond SM; ; Brown MP; Khanna KK Clin Cancer Res; 2014 Jun; 20(12):3187-97. PubMed ID: 24838526 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]